|
US10953089B1
|
|
Coronavirus vaccine formulations
|
|
WO2020176524A1
|
|
Methods for preventing disease or disorder caused by rsv infection
|
|
AU2019238171A1
|
|
Multivalent influenza nanoparticle vaccines
|
|
EP3658118A1
|
|
Methods and compositions for treating respiratory disease
|
|
MX2019010948A
|
|
Methods and compositions for inducing immune responses against clostridium difficile.
|
|
US2017354729A1
|
|
Vaccine compositions containing modified zika virus antigens
|
|
BR112018004242A2
|
|
vaccine compositions having increased stability and immunogenicity
|
|
EP3046579A1
|
|
Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
|
|
AU2014237485A1
|
|
Enhanced expression of picornavirus proteins
|
|
US2016000902A1
|
|
Combination vaccine for respiratory syncytial virus and influenza
|
|
MX2015010305A
|
|
Combination vaccine for respiratory syncytial virus and influenza.
|
|
IL226187D0
|
|
Rabies glycoprotein virus-like particles (vlps)
|
|
CN104080476A
|
|
Recombinant nanoparticle RSV F vaccine for respiratory syncytial virus
|
|
CN103384531A
|
|
Modified influenza hemagglutinin proteins and uses thereof
|
|
MX2013005090A
|
|
RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs).
|
|
AU2011218606A1
|
|
Functional influenza virus-like particles (VLPS)
|
|
WO2011088451A1
|
|
Uses of influenza virus-like particles (vlps) for characterization of neuraminidase and hemagglutinin activity
|
|
WO2011011390A1
|
|
Purified recombinant influenza virus ha proteins
|
|
WO2010148386A1
|
|
Swine-origin influenza a (h1n1) virus-like particles and methods of use thereof
|
|
WO2010077712A1
|
|
Bovine respiratory syncytial virus virus-like particle (vlps)
|
